NICE has recommended regular NHS funding for Takeda’s Adcetris in an aggressive type of non-Hodgkin lymphoma after the company submitted further data to support its case.
NICE has caused controversy by rejecting Pfizer’s Besponsa – a blood cancer drug that can give patients the chance to receive a potentially curative bone marrow transplant.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
